Active Pharmaceutical Ingredient CDMO Market to grow with a CAGR of 6.10%

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Active Pharmaceutical Ingredient CDMO Market.

According to TechSci Research report, “Global Active Pharmaceutical Ingredient CDMO Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2019-2029”, Global Active Pharmaceutical Ingredient CDMO Market has valued at USD 91.98 billion in 2023 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.10% through 2029. This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market. The growing complexity of drug development is a significant driver of the demand for Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) services. Many of the newer drugs under development are biologics or high-potency compounds, which are more complex to manufacture than traditional small-molecule drugs. CDMOs with specialized expertise and infrastructure are needed to handle these complexities. Biologics, including monoclonal antibodies and gene therapies, are at the forefront of drug development. These therapies often require specialized bioprocessing capabilities, making CDMOs with experience in this area highly sought after. High-potency APIs, often used in oncology and rare disease treatments, require stringent containment and handling. CDMOs with dedicated high-containment facilities are crucial to ensure the safety of both workers and the environment. Drug development is inherently risky and expensive. Many pharmaceutical companies choose to mitigate risk by outsourcing certain aspects of the process to CDMOs with the expertise and infrastructure to handle complex development challenges.

Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " Global Active Pharmaceutical Ingredient CDMO Market”

In June 2023, Merck, a prominent science, and technology company, has disclosed the expansion of its facility in Verona, located near Madison, Wisconsin, USA, as part of its Life Science business sector. This expansion, at a cost of €59 million and covering 70,000 square feet, has effectively doubled the company's production capacity for high-potent active pharmaceutical ingredients (HPAPI). In addition to its HPAPI capabilities, Merck boasts extensive experience in the development and manufacturing of Antibody-Drug Conjugates (ADCs). As the inaugural Contract Development and Manufacturing Organization (CDMO) to produce commercially approved ADC drugs in North America, the company has recently introduced innovative technologies aimed at advancing ADC therapies. These include ChetoSensar technology, which addresses solubility challenges and holds promise for ADCs, and the DOLCORE platform, designed to significantly reduce the time required for development and manufacturing, potentially accelerating the delivery of vital therapies to patients by up to a year.

Global geopolitical uncertainties can pose a significant challenge in the Global Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) market. Geopolitical developments can lead to shifts in regulatory requirements and standards. API CDMOs must navigate these changes to ensure continued compliance with regulations, which can be complex and resource intensive. Export restrictions or import tariffs imposed by countries can affect the cost and availability of pharmaceutical ingredients. This can lead to increased expenses and uncertainties in the supply chain. Geopolitical factors can influence market access and expansion strategies for pharmaceutical companies. Uncertainties in market entry and access can affect the demand for API CDMO services. Geopolitical considerations can impact intellectual property protection and enforcement, which is critical for API CDMOs and their pharmaceutical clients. Changes in intellectual property laws and enforcement can affect the protection of API formulas and processes.

Global Active Pharmaceutical Ingredient CDMO Market is segmented based on Product, Synthesis, Drug, Application, and by region.

Based on the Product, Global Active Pharmaceutical Ingredient CDMO Market is segmented into Traditional Active Pharmaceutical Ingredient (API), Highly Potent API, Antibody Drug Conjugate, Others. Highly Potent Active Pharmaceutical Ingredients (HPAPIs) refer to a category of pharmaceutical compounds that are characterized by their high potency and often low therapeutic doses. These are chemical or biological substances used in the manufacture of drugs, particularly those designed for targeted therapies and treatments of conditions such as cancer, autoimmune disorders, and rare diseases. In the context of the Global Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) market, HPAPIs represent a specialized and critical component of pharmaceutical manufacturing. HPAPIs are characterized by their high pharmacological potency. They are effective at low doses, often in micrograms or even nanograms, making them suitable for targeted therapies with minimal side effects.

Based on Region, North America held the largest share in the Global Active Pharmaceutical Ingredient CDMO Market. The North American pharmaceutical market is one of the largest and most diverse in the world. The demand for APIs is consistently high due to the large population, aging demographics, and the prevalence of various health conditions that require pharmaceutical treatment. API CDMOs benefits from being near their pharmaceutical clients. Being geographically close allows for easier collaboration, communication, and faster response to client needs. North America has strong intellectual property protection laws, which are essential for safeguarding the proprietary technologies and formulations that pharmaceutical companies develop. This provides confidence for companies to engage with North American API CDMOs. North America has well-developed infrastructure, including state-of-the-art manufacturing facilities and access to investment capital. This infrastructure supports the growth and expansion of API CDMOs in the region.

Some of the major companies operating in the Global Active Pharmaceutical Ingredient CDMO Market include:

• Cambrex Corporation
• Recipharm AB
• Thermo Fisher Scientific Inc. (Pantheon
• CordenPharma International
• Samsung Biologics
• Lonza Group AG
• Catalent, Inc.
• Siegfried Holding AG
• Piramal Pharma Solutions
• Boehringer Ingelheim International GmbH

Download Free Sample Report

Customers can also request for 10% free customization on this report

“Certain areas, particularly in North America, are projected to exert significant demand for Active Pharmaceutical Ingredient CDMO. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Active Pharmaceutical Ingredient CDMO Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

Active Pharmaceutical Ingredient CDMO Market by Product (Traditional Active Pharmaceutical Ingredient (API), Highly Potent API, Antibody Drug Conjugate, Others), By Synthesis (Synthetic, Biotec), by Drug (Innovative, Generic), by Application (Oncology, Hormonal, Glaucoma, Cardiovascular, Diabetes, others), By Region, By Competition Forecast & Opportunities, 2019-2029F has evaluated the future growth potential of Global Active Pharmaceutical Ingredient CDMO Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Active Pharmaceutical Ingredient CDMO Market.

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]

Website: www.techsciresearch.com